ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AGIO Agios Pharmaceuticals Inc

34.54
-0.04 (-0.12%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Agios Pharmaceuticals Inc NASDAQ:AGIO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.04 -0.12% 34.54 32.83 161.45 35.48 33.63 34.90 807,894 05:00:02

Agios Pharmaceuticals to Webcast Conference Call of Second Quarter 2014 Financial Results on August 7, 2014

28/07/2014 2:00pm

GlobeNewswire Inc.


Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Agios Pharmaceuticals Charts.

Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today announced that it will host a conference call and live webcast on Thursday, August 7, 2014 at 8:30 a.m. EDT to report its second quarter 2014 financial results and discuss recent business activities.

The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 78621204. The webcast will be archived and available for replay on the company's website beginning approximately two hours after the event.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.

CONTACT: Agios Pharmaceuticals:
         Lora Pike
         Senior Director, Investor Relations and Public Relations
         investors@agios.com

1 Year Agios Pharmaceuticals Chart

1 Year Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

1 Month Agios Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock